Under terms disclosed in an 8-K filed with the Securities and Exchange Commission on June 22, AbbVie will pay $135.11 per share for all outstanding Apogee stock — a premium of roughly 49 percent to Apogee’s closing price the prior day. Both companies’ boards of directors unanimously approved the transaction. Closing is expected in the third quarter of 2026, subject to customary conditions including Apogee shareholder approval and receipt of required regulatory clearances.

The acquisition’s centerpiece is zumilokibart (APG777), Apogee’s lead asset — a subcutaneous, half-life-extended monoclonal antibody targeting interleukin-13 (IL-13), a cytokine implicated in allergic inflammation. Zumilokibart is in late-stage clinical development for moderate-to-severe atopic dermatitis and asthma. The drug’s engineered extended half-life is designed to allow maintenance dosing as infrequently as once every three to six months, a potential differentiator in a crowded inflammatory skin-disease market.

In atopic dermatitis, zumilokibart completed Part B of the Phase 2 APEX trial and met its primary endpoint. Apogee had announced plans to launch three Phase 3 trials — ADventure 1, ADventure 2, and ADventure TCS — in moderate-to-severe atopic dermatitis in the second half of 2026. In asthma, an earlier-stage Phase 1b program generated interim data Apogee described as demonstrating rapid and durable suppression of fractional exhaled nitric oxide through 32 weeks. The Vital Record has not independently verified the underlying trial datasets for those efficacy figures.

Apogee’s pipeline also includes APG333 and APG273, additional clinical-stage candidates targeting inflammatory indications, though terms related to those programs were not separately disclosed.

“Apogee’s pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need, including atopic dermatitis and asthma,” AbbVie chief executive Robert Michael said in the announcement.

The acquisition underscores the pressure AbbVie faces to rebuild revenue as Humira, once the world’s best-selling drug, faces deepening biosimilar competition. According to AbbVie’s Q1 2026 earnings release (April 29, 2026), Humira net revenues fell 38.6 percent year-over-year to $688 million in the first quarter of 2026. Skyrizi and Rinvoq — AbbVie’s current immunology growth engines — posted combined global revenues of approximately $6.6 billion in Q1 2026 per the same earnings release, but the company has signaled that further pipeline depth is essential to sustaining long-term growth.

Termination fees and financing details were not prominently disclosed in materials reviewed for this report.

Correction — June 23, 2026: The original article cited Humira net revenues (−38.6% to $688M in Q1 2026) and combined Skyrizi/Rinvoq revenues (~$6.6B in Q1 2026) without identifying their source. Both figures are numerically accurate but come from AbbVie’s Q1 2026 earnings release (April 29, 2026), not from the acquisition 8-K or deal press release cited elsewhere in the story. The attribution has been corrected.

Definium Therapeutics (Nasdaq: DFTX) disclosed the results from its Phase 3 “Emerge” trial in an 8-K filing with the Securities and Exchange Commission on June 22. The study measured change in total score on the Montgomery-Åsberg Depression Rating Scale (MADRS), a clinician-administered instrument widely used as a primary endpoint in antidepressant trials. Patients who received a single oral disintegrating tablet of DT120 showed a MADRS total score that was 8.1 points lower than placebo at Week 6 (p<0.0001).

MADRS is a validated clinician-administered rating scale — not a patient-reported outcome — widely accepted by regulators as a primary endpoint for antidepressant trials, though it measures symptom severity rather than hard clinical endpoints such as hospitalization or mortality, a distinction regulators and payers weigh carefully.

The safety readout was notable. The company reported that 99% of treatment-emergent adverse events were rated mild to moderate in severity, and the trial detected no signal of suicidality — a concern that has historically accompanied fast-acting agents in this class.

If the finding is confirmed in a second Phase 3 trial, DT120 would be the first oral psychedelic-class antidepressant to reach the market. The FDA has not reviewed or approved the drug; a new drug application would require at minimum a second adequate and well-controlled pivotal study, and the agency’s review timeline remains unknown.

The clinical stakes are substantial. Major depressive disorder is among the most prevalent disabling conditions worldwide, affecting tens of millions of Americans, and treatment-resistant depression — a subgroup for whom multiple standard therapies have failed — represents a major unmet need with few approved options. No psychedelic-derived compound has previously succeeded in a Phase 3 trial for major depressive disorder broadly defined. Compass Pathways’ COMP360 (synthetic psilocybin) met its primary endpoint in two Phase 3 trials earlier in 2025–2026, but those trials were specifically in treatment-resistant depression — a distinct, more severely ill subpopulation defined by failure of prior therapies — not in the broader MDD population enrolled in Emerge.

Definium’s shares closed approximately 47% above the prior day’s close on the day of the announcement. Investors should note that a single positive Phase 3 trial does not guarantee regulatory approval, commercial launch, or any particular return — and that a second Phase 3, the full FDA review, and manufacturing scale-up all represent material hurdles between Monday’s topline read and any eventual prescription.

Definium has not disclosed a timeline for initiating a confirmatory study or engaging in a pre-NDA meeting with the FDA.

Correction — June 23, 2026: Three errors have been corrected in this article. (1) The Montgomery-Åsberg Depression Rating Scale (MADRS) was originally described as “a surrogate, patient-reported outcome measure.” MADRS is a clinician-administered rating scale, not patient-reported; this description has been corrected. (2) The DFTX end-of-day stock gain was originally stated as “approximately 53%”; trading data shows the stock closed approximately 47% above its prior close on the day of the announcement, and the figure has been corrected throughout. (3) The original text stated that “no psychedelic-derived compound has previously succeeded in a Phase 3 trial in MDD” without noting that Compass Pathways’ COMP360 psilocybin met its primary endpoint in two Phase 3 trials for treatment-resistant depression before this announcement; a clarifying sentence distinguishing TRD from the broader MDD population enrolled in Emerge has been added.

The offering was expanded from an original $320 million target, a sign of robust institutional demand for a company whose leadership team carries the fingerprints of one of cardiovascular biotech’s biggest exits. Kardigan was co-founded by Tassos Gianakakos, the former chief executive of MyoKardia, and Jay Edelberg, M.D., Ph.D., a veteran of MyoKardia, Sanofi, Bristol Myers Squibb, and GlaxoSmithKline. MyoKardia, which developed the heart drug Camzyos, was acquired by Bristol Myers Squibb in 2020 for $13.1 billion.

Underwriters — J.P. Morgan, Jefferies, Leerink Partners, and TD Securities — hold a 30-day option to purchase up to 3.75 million additional shares.

Pipeline: three bets on under-treated cardiovascular disease

Proceeds are earmarked to advance three clinical-stage candidates. The lead program, danicamtiv, is a cardiac myosin activator in the Phase 2b/3 KINSHIP-DCM trial for genetic dilated cardiomyopathy, with topline data expected in the first half of 2027. Ataciguat, a soluble guanylate cyclase (sGC) activator, is in Phase 2 for calcific aortic valve stenosis, a condition with no approved pharmacological therapy. Tonlamarsen, an antisense oligonucleotide targeting angiotensinogen, is in Phase 2 for acute severe hypertension following hospitalization.

At its debut close of approximately $22, Kardigan commands a market capitalization of nearly $2 billion. The IPO makes Kardigan the fourth biotech in 2026 to raise at least $400 million — the most in a single year since 2021 — and the 13th venture-backed biotech to go public this year, surpassing all of 2025’s total.

As with all pipeline-stage IPOs, Kardigan’s ability to reach the data readouts it has outlined will depend on execution against its clinical timelines and the financial runway the offering provides.

Cytisinicline is an alkaloid derived from the seeds of Laburnum anagyroides, where it occurs naturally as a partial agonist at α4β2 nicotinic acetylcholine receptors — the same receptor subtype targeted by varenicline (Chantix/Champix). The compound has been used as an over-the-counter smoking cessation aid in several Eastern European countries for decades under the name Tabex, but NDA 217082 represents the first application for FDA approval of a cytisinicline product in the United States.

The clinical efficacy package includes two Phase 3 trials conducted by Achieve Life Sciences: ORCA-2 (810 participants) and ORCA-3 (792 participants), for a combined randomized enrollment of 1,602 patients. Both trials demonstrated statistically significant improvements in continuous abstinence rates versus placebo, and the safety profile showed a tolerability advantage over the nausea burden associated with varenicline at standard doses.

Approximately 48 million Americans use tobacco products, according to the CDC’s 2024 National Health Interview Survey data. Existing pharmacotherapy — including varenicline, bupropion, and nicotine replacement therapy — leaves a meaningful proportion of smokers without adequate cessation support. Cytisinicline’s lower cost of goods relative to varenicline has been cited by advocates as a potential access advantage for lower-income populations.

Manufacturing-related CRLs are common in complex natural-product drug applications, where standardizing extraction, purification, and quality control to GMP requirements can require facility upgrades or supply-chain changes. Achieve Life Sciences has stated its intention to respond to the CRL by addressing the manufacturing observations and resubmitting. No resubmission timeline has been disclosed. The clinical program appears intact.

FDA CRL, NDA 217082, cytisinicline, June 19, 2026. ORCA-2 and ORCA-3 trials, Achieve Life Sciences. CDC National Health Interview Survey, 2024.

Pegcetacoplan is a complement C3 inhibitor approved in the United States under the brand names Syfovre (age-related macular degeneration, 2023) and Empaveli (paroxysmal nocturnal hemoglobinuria, 2021). As a Biogen subsidiary, Apellis had been exploring the drug’s potential in kidney transplant recipients on the basis of complement’s role in ischemia-reperfusion injury and transplant-mediated rejection.

The Phase 3 trial (NCT07020832) opened for enrollment on May 18, 2026 — four days after Biogen closed its acquisition of Apellis. The suspension, occurring roughly four weeks after opening, is unusual in its timing — Phase 3 trials typically enroll for months to years before any suspension decision. The absence of a posted explanation leaves the reason unknown: possible causes include a safety signal in early enrollees, a strategic business decision, a manufacturing issue, or a change in protocol design, but Biogen/Apellis has not disclosed the basis.

Neither Biogen nor Apellis issued a press release or 8-K filing describing the suspension as of June 19, 2026. The company’s pipeline page has not been updated. The ClinicalTrials.gov record shows enrollment status as “Suspended.”

The company’s two approved complement inhibitor franchises (Empaveli and Syfovre) address distinct mechanisms — systemic C3 inhibition for PNH versus intravitreal C3 inhibition for GA — and the kidney transplant programme represented an exploratory extension of the systemic indication.

Correction (2026-06-19): The original article attributed the trial and its suspension to “Apellis Pharmaceuticals” without disclosing that Biogen completed its acquisition of Apellis on May 14, 2026 — four days before NCT07020832 opened for enrollment on May 18, 2026. As a wholly owned subsidiary, Apellis decisions were made under Biogen’s corporate oversight. The article has been updated to reflect this corporate context throughout. The timing has also been corrected from “approximately five weeks” to “approximately four weeks” (start date May 18 to article date June 19 = approximately four weeks and one day).

The IPO is the culmination of a capital formation arc that began with a $300 million Series A in January 2025 and continued with a $254 million Series B in October 2025. Management has stated that the combined proceeds support operations and KINSHIP-DCM enrollment into 2028, well past expected Phase 2b topline data.

The drug: danicamtiv and genetic dilated cardiomyopathy

Kardigan’s single clinical-stage program is danicamtiv, an oral, once-daily cardiac myosin activator originally discovered at MyoKardia (as MYK-491). MyoKardia was acquired by Bristol-Myers Squibb in November 2020 for $13.1 billion; BMS subsequently divested the danicamtiv program, and Kardigan entered into an arm’s-length license agreement with BMS on November 4, 2024 to acquire exclusive worldwide rights.

Danicamtiv is mechanistically the complement of Camzyos (mavacamten, approved by FDA April 28, 2022 for obstructive hypertrophic cardiomyopathy): where mavacamten inhibits overactive cardiac myosin, danicamtiv activates it — recruiting myosin molecules from the autoinhibited “super-relaxed” OFF state into the actin-accessible, force-generating ON state. The target indication, genetic and familial dilated cardiomyopathy (DCM), is a disease of contractile insufficiency, not overcontraction. DCM causes left ventricular dilation and systolic dysfunction; in its genetic form, the most common causative genes are TTN (titin, 12–25% of cases) and MYH7 (beta-myosin heavy chain, ~5%).

No drug is currently FDA-approved specifically for genetic or familial DCM.

Phase 2a data: what the JACC paper showed

Kardigan presented pivotal Phase 2a data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in September 2025; the full paper was published in the Journal of the American College of Cardiology in December 2025 (PMID 41217321).

The study (NCT04572893), a Phase 2a, open-label, exploratory trial sponsored originally by BMS, enrolled 41 patients with genetic DCM in three pre-specified cohorts: MYH7 (n=12), TTN (n=14), and Other Causes (n=15). After two consecutive treatment periods at danicamtiv 25 mg twice daily:

• MYH7 cohort: absolute LVEF change +8.8 percentage points (95% CI, 5.03–12.64; p = 0.001); left atrial function index (LAFI) change +11.1 (p = 0.006)
• TTN cohort: absolute LVEF change +5.9 percentage points (95% CI, 2.59–9.28; p = 0.005)
• Other causes cohort: LVEF change +4.4 percentage points (95% CI, −0.90 to 9.73; p = NS)

All adverse events were mild or moderate; no drug-related serious adverse events, no deaths.

The differential response between MYH7 and TTN is mechanistically coherent: MYH7 variants directly impair the myosin motor, so activating residual myosin restores function most directly; TTN variants reduce the quantity of functional myosin available, so the activating benefit is more attenuated. Open-label extension data in 19 patients were presented at ACC 2026 and published in JACC April 2026.

KINSHIP-DCM: the pivotal trial

KINSHIP-DCM (NCT07210723) is a Phase 2b/3, adaptive, randomized, double-blind, placebo-controlled trial enrolling patients with symptomatic genetic or familial DCM regardless of specific gene — covering MYH7, TTN, and other identified DCM-associated variants. The trial opened on February 13, 2026 and is currently recruiting across 43 sites in 9 countries (including Brigham and Women’s, Mayo Clinic, UCSF, and Hammersmith Hospital). Target enrollment is 332 patients; the Phase 2b interim analysis (primary endpoint: change in left atrial function index at 26 weeks) is expected in H1 2027.

Kardigan’s leadership team includes Tassos Gianakakos (CEO; co-founder; previously CEO of MyoKardia, a role he assumed in October 2013), Jay Edelberg, MD, PhD (CMO), and Bob McDowell, PhD (CSO). Gianakakos oversaw the Phase 2a data generation and the BMS license negotiation before leading the Kardigan founding.

The company reported a net loss of $56.1 million in Q1 2026 and has no product revenue.

Correction — June 18, 2026: An earlier version of this article stated KINSHIP-DCM is enrolling across 43 sites in 10 countries. ClinicalTrials.gov (NCT07210723) lists sites in 9 countries: United States, Denmark, France, Hungary, Italy, Poland, Spain, Sweden, and United Kingdom. Corrected to 9 countries. Identified by The Vital Record’s post-publication fact-check.

About the therapy

Lonvo-z (INN: lonvoguran ziclumeran) is an investigational in vivo gene-editing treatment based on CRISPR/Cas9 technology designed to permanently silence the KLKB1 gene, which encodes plasma kallikrein B1. By reducing kallikrein activity and downstream bradykinin production, the single-dose treatment aims to address the root cause of HAE attacks. Lonvo-z has not been approved by any regulatory agency.

Trial design

The Phase 3 HAELO trial enrolled 80 patients with Type 1 or Type 2 HAE, randomised 2:1 to receive a single intravenous dose of lonvo-z (n=52) or placebo (n=28). The primary efficacy evaluation period ran from week 5 through week 28 post-dose.

Efficacy (all figures per the company)

• Mean monthly attack rate: 0.26 (lonvo-z) vs. 2.10 (placebo) — 87% reduction (95% CI: −93% to −78%; P<0.001)
• Attack-free patients: 62% (lonvo-z) vs. 11% (placebo) — odds ratio 12.8 (95% CI: 3.5–47.6; P<0.0001)
• Reduction in attacks requiring on-demand treatment: 89%, the company said
• Reduction in moderate-to-severe attacks: 91%, the company said

These figures are derived from Intellia’s press release and have not been independently verified by this publication from the primary NEJM paper; readers should refer to the published manuscript for the complete data.

Safety (per the company)

All treatment-emergent adverse events were mild to moderate in severity; no serious adverse events were observed.

Regulatory status

Lonvo-z holds Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. A rolling Biologics License Application (BLA) has been initiated, the company said, with target BLA submission completion in 2H 2026 and potential US launch in 1H 2027 — timelines that are subject to regulatory review and not guaranteed.

Lonvo-z is an investigational therapy that has not been approved by the FDA or any other regulatory agency. This article does not constitute an endorsement of this therapy or a recommendation to seek or alter treatment.

The centerpiece of the deal is Firefly’s Firelink platform, co-founded with Carolyn Bertozzi, the Stanford chemist who shared the 2022 Nobel Prize in Chemistry for her foundational work in bioorthogonal and click chemistry. Where a classical ADC couples an antibody to a cytotoxic payload — essentially using a targeting missile to deliver chemotherapy — Firelink swaps in a targeted protein degrader. The antibody ferries the degrader molecule into tumour cells, where it commandeers the cell’s own proteasomal machinery to eliminate a disease-driving protein.

The intended target is KRAS, a small GTPase mutated in roughly 25 percent of the most common solid tumours, including nearly all pancreatic cancers and up to 40 percent of colorectal cancers. KRAS-driven malignancies have historically frustrated drug developers; the protein’s smooth surface offered few obvious binding pockets for small molecules. Recent approvals of direct KRAS inhibitors have opened the door, but resistance and selectivity limitations remain active problems. The DAC approach represents a distinct mechanistic bet: rather than blocking KRAS activity, it aims to remove the protein from the cell entirely.

Firelink is preclinical. J&J is acquiring a platform and an early-stage pipeline, not a drug with Phase 3 validation. The $1 billion figure reflects the company’s assessment of the technology’s potential, not demonstrated clinical efficacy. No milestone payments or contingent value terms were disclosed.

The acquisition fits a visible pattern: established oncology franchises acquiring next-generation payload-delivery platforms before clinical proof of concept drives prices higher. For J&J, it extends an oncology build-out that has included multiple recent platform and asset transactions.

Shares opened at $33.35 on June 10, up 66.75 percent from the offer price, on the first day of trading.

The Cambridge, Massachusetts company — founded as FogPharma by chemist Gregory Verdine in 2015 and rebranded as Parabilis in 2024 — is developing a class of medicines it calls Helicon peptides: stabilized, cell-penetrant alpha-helical molecules engineered to reach intracellular protein targets that have resisted both small molecules and biologics. The company had raised more than $800 million in private financing before going public.

Concurrent with the IPO, Regeneron Pharmaceuticals purchased 4.166 million shares at $18.00 per share — 90 percent of the offer price — generating approximately $75 million in additional proceeds as part of a broader research collaboration. The collaboration, announced in May, carries potential value of up to approximately $2.325 billion, comprising a $50 million upfront payment, the $75 million equity commitment, and up to $2.2 billion in milestone payments. The two companies will work jointly to create antibody-Helicon conjugates — a novel drug class designed to deliver Helicon payloads to difficult intracellular targets — across five initial oncology programs, with Regeneron retaining worldwide development and commercialization rights.

Parabilis’s lead program, zolucatetide (formerly FOG-001), is the first direct inhibitor of the beta-catenin/TCF protein-protein interaction, a node in the Wnt signaling pathway long considered undruggable. The drug is currently in dose-expansion stages of a Phase 1/2 trial in desmoid tumors, a rare soft-tissue cancer driven by Wnt pathway mutations, where it has demonstrated a disease control rate of 100 percent and a 74 percent objective response rate in early data. Zolucatetide holds FDA Fast Track and Orphan Drug designations for that indication; the company plans to initiate a Phase 3 trial in the first half of 2027. Parabilis has earmarked approximately $150 million of IPO proceeds for continued zolucatetide development in desmoid tumors.

ISLEND-1 (NCT06630286) enrolled virologically suppressed adults living with HIV-1 and randomized them to an islatravir-based once-weekly oral regimen versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF) — Gilead Sciences’ once-daily integrase inhibitor backbone widely considered the current clinical standard for maintenance therapy. ISLEND-2 (NCT06630299) evaluated a similar islatravir-based once-weekly regimen against a broader range of standard-of-care daily oral antiretroviral therapy regimens, expanding the comparator landscape.

Both trials met their primary virologic suppression endpoint. Merck did not release specific response rates or confidence intervals in its June 8 announcement; detailed data are expected at a forthcoming medical meeting.

Why weekly dosing matters

Daily oral antiretroviral therapy is transformative — but it imposes a lifelong adherence burden. Missed doses, even intermittently, risk viral rebound and the selection of resistance mutations in some regimens. Islatravir belongs to the NRTTI class; its prolonged intracellular half-life makes it pharmacologically suited for weekly dosing by maintaining sustained intracellular drug levels between doses. Approximately 1.2 million Americans and 39 million people globally live with HIV; a once-weekly oral option would meaningfully reduce the daily treatment reminder for those currently on daily therapy.

Safety context

Islatravir is investigational and is not approved by the FDA or any regulatory authority for HIV treatment. Earlier Phase 2 studies of islatravir in combination with other agents observed CD4+ T-lymphocyte count decreases in some participants, prompting study design modifications; the ISLEND Phase 3 program incorporates CD4+ monitoring. How this signal may affect the final benefit-risk profile will become clearer when full Phase 3 safety data are published.

Merck did not specify a regulatory submission timeline in the June 8 topline announcement.

This report is based on a corporate topline announcement; full data have not been published or peer-reviewed.

Correction, June 10, 2026: The original article attributed the ISLEND program and its topline announcement solely to Merck and described the investigational drug as “islatravir-based” without naming the co-drug. Post-publication fact-check against ClinicalTrials.gov (NCT06630286, NCT06630299) confirmed that both ISLEND trials list Gilead Sciences as the primary registered sponsor, with Merck Sharp & Dohme LLC as collaborator, and that the investigational regimen combines islatravir (Merck’s NRTTI) with lenacapavir (Gilead’s HIV-1 capsid inhibitor). The opening paragraph and article framing have been updated accordingly.

Not approved, not yet prescribable — and for narrow patient subsets. Both lead assets are investigational and under FDA review; neither is approved or available for prescription, and there is no guarantee either will be cleared. Each is aimed not at lung cancer broadly but at a small, genetically defined subset of non-small-cell lung cancer (NSCLC): zidesamtinib at tumors carrying a ROS1 alteration (ROS1 rearrangements occur in roughly 1–2% of NSCLC) and neladalkib at tumors carrying an ALK alteration (ALK rearrangements in roughly 3–5%). If either is approved, eligibility would be limited to patients whose tumors carry the specific ROS1 or ALK alteration, confirmed by molecular (biomarker) testing; patients with other forms of lung cancer would not be candidates. This is a business and regulatory report, not medical advice — treatment decisions belong with a patient’s oncology team.

The wager rests on two next-generation kinase inhibitors built for these subsets. Both are designed for selectivity — to hit the mutant target while sparing the wild-type protein that drives off-target toxicity — and to stay active in the brain, a common site of metastasis. GSK is also acquiring a third clinical asset, NVL-330 (a HER2 inhibitor in Phase 1), and a preclinical portfolio, though the deal’s value rests on the two lead programs.

Two assets, two looming decisions

The lead asset, zidesamtinib (NVL-520), is an investigational, selective ROS1 inhibitor for ROS1-positive NSCLC, studied in the Phase 1/2 ARROS-1 trial (NCT05118789, sponsored by Nuvalent). Per ClinicalTrials.gov, the Phase 2 portion’s primary endpoint is objective response rate (ORR) assessed by blinded independent central review (BICR); the registry shows no results posted. GSK says the drug is under FDA review with a target decision date of September 18, 2026.

The second, neladalkib (NVL-655), is an investigational, selective ALK inhibitor for ALK-positive NSCLC, evaluated in the Phase 1/2 ALKOVE-1 study (NCT05384626) and now in the first-line Phase 3 ALKAZAR trial (NCT06765109). ALKAZAR is randomizing 450 patients 1:1 (about 225 per arm) against alectinib, with progression-free survival (PFS) by blinded independent central review as the primary endpoint. GSK puts neladalkib’s FDA target decision date at November 27, 2026.

“Today’s acquisition is a multi-product deal,” said GSK chief executive Luke Miels, describing it as “consistent with our approach to acquire assets that have clinically proven targets.”

Neither candidate is approved, and the efficacy data underpinning the filings have not been posted to the trial registry, so no response or survival figures can be independently verified here. On the financial impact, GSK said it expects low-single-digit percentage dilution to core earnings per share in the current year and in 2027 and 2028; it expects the deal to turn accretive to core operating profit in 2027 and to core EPS in 2029.

The asset is VGA039, an investigational monoclonal antibody that, per the company, modulates Protein S — a natural anticoagulant — to improve hemostasis. Its lead indication is von Willebrand disease (VWD), which the company describes as the most common inherited bleeding disorder and says affects roughly 135,000 diagnosed patients in the United States. The pitch is convenience: VGA039 is dosed subcutaneously, against current factor-replacement prophylaxis that the company says can require two to three intravenous infusions a week.

A Phase 3 still gathering data

VGA039 sits in the Phase 3 VIVID-6 study (NCT07115004). Per ClinicalTrials.gov, it is an open-label, single-sequence crossover trial enrolling about 60 patients aged 12 to 75 with any VWD type and a historical annualized bleeding rate of at least 12. Patients undergo an observational period of at least 24 weeks before roughly 49 weeks of treatment; the primary endpoint is the incidence of bleeding events. The registry’s exclusion criteria are notable given the mechanism: patients with prothrombotic disorders or a history of arterial or venous thrombosis are barred — a reminder that the drug works by blunting a natural anticoagulant. The trial is recruiting, with completion projected for October 2028. No results have been posted.

Incyte CEO Bill Meury called VGA039 “a first-in-class, Phase 3 asset with compelling early data” — a characterization that no peer-reviewed efficacy data yet substantiate, and the trial registry confirms no results have been reported.

VGA039 holds FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations. Incyte expects to close in the third quarter of 2026, pending Hart-Scott-Rodino clearance, and to book an R&D charge of about $1.25 billion.

The structure is closer to a partnership than a licensing handoff. In the United States, the two firms will share development costs 40/60 — Nurix 40%, Roche 60% — and split US profits and losses equally across all indications. Outside the US, Roche takes commercialization, paying Nurix royalties the companies describe only as “ranging from the low- to high-teens.” Both figures come from Nurix’s own announcement and are corroborated by Roche’s release; The Vital Record could not independently access Nurix’s Form 8-K to confirm the milestone breakdown.

A degrader, not a blocker

Bexobrutideg is an oral, brain-penetrant small molecule that the companies say eliminates the BTK protein from cells rather than merely blocking its kinase activity — the mechanism that distinguishes degraders from established BTK inhibitors. That premise is now being tested where it matters most: directly against a marketed competitor.

ClinicalTrials.gov lists a Phase 3 trial (NCT07516093) of bexobrutideg versus pirtobrutinib in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, with planned enrollment of 620 patients. It is marked not yet recruiting, with a June 2026 start. A single-arm Phase 2 (NCT07221500, 100 patients) in CLL/SLL previously treated with both a BTK inhibitor and a BCL-2 inhibitor is recruiting, and the foundational Phase 1 dose-escalation study (NCT05131022) lists 572 participants.

The companies frame ambitions beyond oncology — chronic spontaneous urticaria and multiple sclerosis — but the registry’s pivotal program is, for now, the CLL head-to-head.

For Roche, the deal extends a deliberate push into targeted protein degradation. For Nurix, the $700 million is by far its largest single payment to date and, per chief executive Arthur Sands, “a major step” toward becoming a fully integrated company. No efficacy or safety figures are reported here: bexobrutideg remains investigational, and no readouts from the pivotal trials have been published. This is not investment advice.

The prize is VGA039, an investigational monoclonal antibody. Despite the deal’s framing around von Willebrand disease (VWD), the antibody does not target von Willebrand factor directly: per Incyte, it modulates Protein S to improve hemostasis. The company describes it as a potential first subcutaneous, once-monthly prophylactic option for patients with VWD, the most common inherited bleeding disorder, who often rely on two to three intravenous infusions a week.

What the trial actually shows so far

VGA039 is in the Phase 3 VIVID-6 study (NCT07115004), which the registry lists as recruiting with a planned enrollment of 60. It is an open-label, single-sequence cross-over design — there is no concurrent control arm — pairing an observational period of at least 24 weeks with roughly 49 weeks of active treatment. The primary endpoint is the incidence of bleeding events; secondary endpoints include treated-bleed incidence, safety, drug levels and anti-drug antibodies. Primary completion is not expected until October 2028, and no Phase 3 results have been posted.

The data behind Incyte’s interest come from an earlier, much smaller study. At the December 2025 ASH annual meeting, Star presented interim Phase 1/2 multidose results: as of a November 14, 2025 cutoff, 16 patients were enrolled, with efficacy data available on the 8 who had completed dosing. The company reported annualized-bleeding-rate (ABR) reductions of 73-87% in prophylaxis-naive patients with a baseline ABR of 12 or more — the same threshold VIVID-6 requires — and 75-100% in patients switching from prior intravenous factor prophylaxis, and called the once-monthly subcutaneous regimen “safe and well tolerated.” These are interim, open-label, single-arm, company-reported figures in just 8 evaluable patients, with no control group and no confidence intervals disclosed; they are early signals, not established clinical benefit.

VGA039 fits directly into our strategy of building a top-tier growth company for the future. — Bill Meury, Incyte CEO

The FDA has granted VGA039 Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations. The transaction, approved by both boards, is expected to close in the third quarter of 2026 pending Hart-Scott-Rodino review. This is not investment advice.

VISIONARY is a randomized, double-blind, placebo-controlled study of sibeprenlimab 400 mg given subcutaneously every four weeks against placebo in biopsy-confirmed IgA nephropathy, per ClinicalTrials.gov. The trial’s primary endpoint is the relative change in urinary protein-to-creatinine ratio at nine months — the basis for the accelerated approval granted November 25, 2025. The annualized eGFR slope over 24 months is a prespecified secondary endpoint (Otsuka calls it the key secondary); the registry also lists mean eGFR change from baseline over 24 months as a separate secondary. As of this writing, ClinicalTrials.gov shows no posted results for the trial.

What the interim showed

The figures below come from Otsuka’s ERA 2026 presentation as relayed in the company’s press release; they are interim secondary-endpoint data, not a peer-reviewed paper, and the registry has not posted results. In the interim analysis (320 randomized; 152 sibeprenlimab, 168 placebo), two distinct 12-month eGFR endpoints were reported.

On total eGFR change from baseline at 12 months, the treated arm was essentially flat (+0.7 mL/min/1.73 m²; 95% CI −0.9 to 2.3), while placebo fell 4.8 points (−4.8; 95% CI −6.3 to −3.3) — a between-arm difference of 5.5 (95% CI 3.4 to 7.6). Note that the drug arm’s own confidence interval crosses zero, so the result rests on the between-arm comparison, not on an individually significant gain.

On the annualized eGFR slope — a different metric over the same 12 months — both arms were still declining: −3.0 mL/min/1.73 m²/year (95% CI −4.6 to −1.4) on sibeprenlimab versus −7.6 (95% CI −9.1 to −6.1) on placebo, a slope difference of 4.6 per year (95% CI 2.5 to 6.8). In other words, the “flat” characterization applies to the total change-from-baseline endpoint, not to the slope, where the treated arm continued to lose function more slowly than placebo rather than holding steady.

The total-change endpoint looks flat; the slope endpoint still declines. They are not the same number, and only one supports “preserved.”

Sibeprenlimab is a monoclonal antibody targeting APRIL, upstream of the pathogenic IgA that drives the disease. On safety, infections occurred in 49% of sibeprenlimab-treated versus 45% of placebo-treated patients, and injection-site reactions in 24% versus 23% — rates similar to placebo.

According to Otsuka’s release, the rolling sBLA for traditional approval already “includ[es] data from the 24-month eGFR endpoint.” That framing sits somewhat uneasily next to VISIONARY’s design as a roughly 24-month study, and none of the 24-month results have been published or posted to the registry. What remains genuinely outstanding, then, is not whether a 24-month analysis exists but FDA review of the conversion filing and independent, peer-reviewed disclosure of the full dataset.

Sevasemten is an investigational, oral, first-in-class fast skeletal myosin inhibitor designed to limit the muscle damage caused by absent or non-functional dystrophin. It is not approved by any regulator. It is being studied in late-stage trials in Becker and Duchenne muscular dystrophy and holds FDA orphan-drug, rare-pediatric-disease and fast-track designations, plus EMA orphan-drug designations — none of which is a marketing approval. Edgewise says that, if approved, it would be the first therapy indicated for Becker, a rare X-linked disorder affecting roughly 12,000 people across the U.S., EU-5 and Japan. No controlled efficacy has been demonstrated to date.

The pivotal read is still ahead. The GRAND CANYON Becker cohort is fully enrolled at 175 participants and, by design, powered at greater than 98% to show a statistically significant difference versus placebo, with top-line data expected in the fourth quarter of 2026 — after the deal is slated to close in the third quarter. No primary efficacy results have been posted; the company’s reference to “sustained disease stabilization” comes from the open-label MESA extension, where participants maintained stable North Star Ambulatory Assessment scores, not from a placebo-controlled endpoint.

Why Edgewise sells now

The cash recasts Edgewise around its cardiac sarcomere modulators. Management says proceeds, combined with existing cash, will fully fund EDG-7500 in hypertrophic cardiomyopathy (Phase 2) through potential approval, with EDG-15400 (HFpEF, Phase 1) and EDG-003 behind it. The company also reaffirmed plans to report 12-week data from Part D of the CIRRUS-HCM trial of EDG-7500 in the second quarter of 2026.

“This transaction delivers immediate, significant value… while placing sevasemten with an acquirer that has the global scale,” said CEO Kevin Koch.

For Servier, President Olivier Laureau framed the buy as “an immediate platform” in neuromuscular disease ahead of the group’s 2030 ambitions. The deal awaits Hart-Scott-Rodino clearance and is expected to close in the third quarter of 2026.

The economics follow the now-familiar AI-biotech template: a modest upfront against a large, back-loaded headline. The $30 million combines cash and an equity investment in Inceptive. Everything beyond it is contingent on Inceptive earning preclinical, regulatory, and commercial-sales milestones across the programs the two companies pursue together. Royalty terms were not disclosed.

What each side brings

The collaboration aims to advance siRNA design by modeling target mRNAs and jointly searching sequence space for novel chemical modifications. Alnylam supplies the asset that is hardest to replicate: more than 20 years of proprietary siRNA data and an R&D engine with six approvals behind it. Inceptive supplies what it calls AI “foundation models of life” — sequence-based models meant to replace some of the trial-and-error screening of thousands of molecules.

“Most drug design still works through a process of trial and error, testing thousands of molecules.” — Jakob Uszkoreit, Inceptive

The number of targets and programs was not specified. Notably, neither company has reported a molecule, an animal result, or a development candidate from the partnership — this is a discovery-stage bet on a method, not on data. Whether AI sequence design beats Alnylam’s established chemistry is precisely the question the next several years are meant to answer.

In RASolute 302, an international, open-label, randomized trial, 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC) were assigned to daraxonrasib (248 patients) or chemotherapy of the investigator’s choice (252 patients). Of those enrolled, 91.8 percent carried RAS G12 mutations. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor that targets the active, GTP-bound state of both mutant and wild-type RAS — the pathway aberrantly activated in more than 90 percent of pancreatic ductal adenocarcinoma cases.

What the trial measured

The trial had dual primary endpoints: overall survival (OS) and progression-free survival (PFS), both assessed in the subpopulation of patients with G12 mutations. In that G12 population, median overall survival was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy, a hazard ratio of 0.40 (P<0.001). In the overall population — which also included patients with G13 or Q61 mutations or no identified mutation — median OS was 13.2 months versus 6.7 months, again a hazard ratio of 0.40 (P<0.001), corresponding to a 60 percent reduction in the risk of death.

Median overall survival was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy in the G12 population, a hazard ratio of 0.40.

Progression-free survival moved in the same direction. In the G12 population, median PFS was 7.3 months with daraxonrasib versus 3.5 months with chemotherapy (hazard ratio 0.45); in the overall population it was 7.2 versus 3.6 months (hazard ratio 0.49), with P<0.001 for both comparisons. Objective response and patient-reported quality of life were among the key secondary endpoints, alongside OS and PFS in the overall population.

On tolerability, treatment-emergent adverse events were reported in all daraxonrasib-treated patients and in 97.7 percent of chemotherapy patients. Grade 3 or higher adverse events were actually less frequent with daraxonrasib (61.8 percent) than with chemotherapy (69.6 percent). Treatment-related adverse events leading to discontinuation occurred in 1.2 percent of the daraxonrasib group versus 11.2 percent of the chemotherapy group.

A few caveats temper the numbers. Crucially for patients, daraxonrasib is investigational: it is not approved by the FDA or any other regulator for previously treated metastatic pancreatic cancer, or any indication, and is therefore not a currently available treatment. On May 1, 2026, the FDA authorized an expanded-access protocol allowing eligible U.S. patients with previously treated mPDAC to obtain the drug through their physicians while it remains under review, but expanded access is not the same as approval. The trial was also open-label, so patients and investigators knew which treatment was given — a design that can introduce bias, though OS is a relatively objective endpoint. The study was funded by Revolution Medicines, and several authors are company employees. Per the ClinicalTrials.gov registry (NCT06625320), the primary completion date was June 2026, so these are the pivotal readout data rather than a final, fully mature dataset; results had not been posted to the registry at the time of publication. The trial enrolled patients with documented RAS status who had received one prior line of 5-fluorouracil-based or gemcitabine-based therapy.

The authors conclude that, among patients with previously treated mPDAC, daraxonrasib led to significantly longer overall and progression-free survival than chemotherapy. This is a peer-reviewed report, not a preprint, and reflects human clinical data rather than preclinical findings. This article is journalism and not medical or investment advice.

VIKTORIA-1 (NCT05501886) is an open-label, randomized Phase 3 study that enrolled 701 patients with HR+/HER2- advanced breast cancer who had progressed on a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor. Patients were randomized by PIK3CA mutation status. The primary endpoint is progression-free survival by blinded independent central review under RECIST v1.1; overall survival and overall response rate are secondary. No results are posted to the trial registry as of this writing.

In its May 1 topline release, Celcuity said the gedatolisib triplet showed a “statistically significant and clinically meaningful improvement in progression-free survival” over alpelisib, a PI3Kα inhibitor, plus fulvestrant. A secondary, non-hierarchical comparison of the two-drug gedatolisib doublet (gedatolisib plus fulvestrant) against the alpelisib doublet also showed a statistically significant and clinically meaningful PFS improvement, per the company. Both gedatolisib regimens were “generally well tolerated, with manageable safety profiles, and no new safety signals,” the release said. No adverse-event rates, dose interruptions, or discontinuation data have been released; the tolerability characterization is the company’s and cannot yet be checked against trial data.

The numbers aren’t public yet

What that release did not contain: a hazard ratio, a confidence interval, median PFS for any arm, or the cohort’s patient count. The detailed results are slated for a late-breaking abstract oral session at the 2026 ASCO Annual Meeting in Chicago on June 2, 9:45 a.m. to 12:45 p.m. CDT. Separately, Celcuity is hosting its own management webcast and conference call at 8:00 a.m. EDT the same day to discuss the results.

The headline is real; the effect size is still a press-release adjective, not a number.

For context, this is not a class of drugs that should be read as low-risk. PI3K/AKT/mTOR pathway inhibitors as a group are generally associated with clinically significant toxicities — including hyperglycemia, rash and in some cases severe cutaneous reactions, diarrhea, and stomatitis — and the alpelisib comparator itself carries known serious risks of hyperglycemia and hypersensitivity reactions in its approved use. None of this is treatment guidance, and the VIKTORIA-1 regimens’ actual safety profile cannot be assessed until the trial data are released.

Co-principal investigator Sara Hurvitz, MD, senior vice president of the clinical research division at Fred Hutch Cancer Center, said in the release that patients with PIK3CA-mutant HR+/HER2- advanced breast cancer whose disease progresses on or after a CDK4/6 inhibitor “typically derive modest benefit from subsequent therapies that target only PI3Kα or AKT.” Celcuity says it intends to submit the data to the FDA as a supplemental New Drug Application; a separate July 17, 2026 PDUFA date already stands for gedatolisib in the PIK3CA wild-type cohort. The ASCO data will decide how meaningful the mutant-cohort win is.